What's Happening?
Merck, known as MSD outside the U.S. and Canada, announced positive topline results from its pivotal Phase 2b/3 BRUNELLO trial for remigromig (MK-3000, formerly EYE103), an investigational treatment for diabetic macular edema (DME). The study, which enrolled
984 participants, demonstrated that both tested doses of remigromig (0.5 mg and 0.8 mg) achieved non-inferiority to the active control 0.5 mg ranibizumab in terms of mean change from baseline in best-corrected visual acuity (BCVA) at week 52. Remigromig is a tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, which is crucial for the repair and maintenance of the blood-retinal-barrier. While generally well tolerated, higher rates of proliferative diabetic retinopathy (PDR), vitreous hemorrhage, and treatment discontinuations due to adverse events were observed in the remigromig arms compared to ranibizumab. Further analyses are underway to characterize these findings. This marks the first new mechanism of action in 20 years to achieve Phase 3 results non-inferior to anti-VEGF therapy for DME.
Why It's Important?
Diabetic macular edema (DME) is a significant cause of vision loss for individuals with diabetes, affecting an estimated 1.6 million people in the United States. The prevalence of DME is expected to increase with the rising incidence of diabetes. Despite existing treatments, up to 40% of patients do not fully respond or only partially respond to current therapies, highlighting a critical unmet need for new and effective treatment options. Merck's remigromig, with its novel mechanism of action targeting the Wnt pathway, represents a potential breakthrough in addressing this challenge. If approved, it could offer a new therapeutic avenue for patients who do not adequately respond to current anti-VEGF treatments, potentially preserving vision and improving the quality of life for a substantial patient population. The development also signifies a shift in the treatment landscape for retinal vascular diseases, introducing a new approach after two decades.
What's Next?
The year one results of the BRUNELLO trial will be presented at the American Academy of Ophthalmology (AAO) Annual Meeting on October 10. Following this, Merck plans to discuss these findings with regulatory authorities, which is a crucial step towards potential regulatory approval. Remigromig is also being evaluated in another pivotal Phase 2b/3 study, the BAROLO study, for DME, and a Phase 2 proof-of-concept study (SUPER TUSCAN) for neovascular age-related macular degeneration (NVAMD) and macular edema secondary to retinal vein occlusion (RVO). Additionally, Merck is developing MK-8748 (Tiespectus, EYE201), another investigational bispecific antibody, in multiple Phase 2b/3 and Phase 3 trials for NVAMD and DME. These ongoing studies indicate Merck's commitment to expanding its ophthalmology pipeline and bringing more innovative treatments to market for various retinal diseases.
Beyond the Headlines
The success of remigromig in its pivotal trial could usher in a new era of treatment for diabetic macular edema, moving beyond the current reliance on anti-VEGF therapies. The Wnt pathway, targeted by remigromig, plays a vital role in blood-retinal-barrier repair and maintenance, suggesting a more fundamental approach to addressing the underlying pathology of DME. The observed higher rates of certain adverse events in the remigromig arms will require careful consideration and further analysis to fully understand the risk-benefit profile. If approved, the introduction of a treatment with a novel mechanism of action could lead to more personalized treatment strategies for DME patients, potentially improving outcomes for those who are currently underserved. This development also underscores the continuous innovation in the biopharmaceutical sector to tackle complex diseases with significant public health impact.
